Canagliflozin: effects in overweight and obese subjects without diabetes mellitus.
Bottom Line: Canagliflozin increased urinary glucose excretion in a dose-dependent manner and produced statistically significant reductions in body weight compared with placebo (least squares mean percent changes from baseline of -2.2%, -2.9%, -2.7%, and -1.3% with canagliflozin 50, 100, and 300 mg and placebo; P < 0.05 for all comparisons).Canagliflozin was associated with higher rates of genital mycotic infections in women, which were generally mild and led to few study discontinuations.In overweight and obese subjects without diabetes mellitus, canagliflozin significantly reduced body weight compared with placebo and was generally well tolerated.
Affiliation: Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA.Show MeSH
Related in: MedlinePlus
Mentions: Canagliflozin increased UGE/creatinine ratio in a dose-dependent manner (Figure 3), beginning at Week 3 (earliest post-randomization assessment time point) and continuing through Week 12. At Week 12 compared to baseline, canagliflozin 50, 100, and 300 mg produced mean changes in UGE/creatinine ratio of 11.9, 18.7, and 30.9 mg/mg, respectively, versus 0.0 mg/mg with placebo. At Week 12 compared to baseline, canagliflozin 50, 100, and 300 mg produced mean overnight RTG values of 82.8, 79.7, and 67.8 mg/dL, respectively – an effect beginning at the first post-randomization visit (Week 3) and maintained throughout the treatment period.
Affiliation: Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA.